Impact of disease heterogeneity on treatment efficacy of immunotherapy in Type 1 diabetes: Different shades of gray

Immunotherapy

Volumn 7, Issue 2, 2015, Pages 163-174

  Woittiez, Nicky J C ^a   Roep, Bart O ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

disease heterogeneity; heterogeneity; immunotherapy; personalized medicine; Type 1 diabetes

Indexed keywords

AUTOANTIBODY;

AGE; ANTIBODY AFFINITY; CLINICAL EFFECTIVENESS; CYTOKINE RESPONSE; DIABETIC PATIENT; DISEASE COURSE; GENDER; GLYCEMIC CONTROL; HLA SYSTEM; HUMAN; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RACE; REVIEW; TREATMENT OUTCOME; CLASSIFICATION; IMMUNOLOGY; PATHOLOGY; PROCEDURES;

DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNOTHERAPY;

EID: 84923923735     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.14.104     Document Type: Review

References (57)

1. Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y. A proposal of three distinct subtypes of Type 1 diabetes mellitus based on clinical and pathological evidence. Ann.s Med. 32(8), 539-543 (2000).
2. Greenbaum CJ, Beam CA, Boulware D et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes 61(8), 2066-2073 (2012).
3. Von Herrath M, Sanda S, Herold K. Type 1 diabetes as a relapsing-remitting disease? Nat. Rev. Immunol. 7(12), 988-994 (2007).
4. Von Herrath M, Peakman M, Roep B. Progress in immune-based therapies for Type 1 diabetes. Clin. Exp. Immunol. 172(2), 186-202 (2013).
5. Roep BO, Buckner J, Sawcer S, Toes R, Zipp F. The problems and promises of research into human immunology and autoimmune disease. Nat. Med. 18(1), 48-53 (2012).
6. Kleijwegt FS, Roep BO. Infectious tolerance as candidate therapy for Type 1 diabetes: transfer of immunoregulatory properties from human regulatory T cells to other T cells and proinflammatory dendritic cells. Crit. Rev. Immunol. 33(5), 415-434 (2013).
7. Ludvigsson J, Krisky D, Casas R et al. GAD65 antigen therapy in recently diagnosed Type 1 diabetes mellitus. N. Engl. J. Med. 366(5), 433-442 (2012).
8. Wherrett DK, Bundy B, Becker DJ et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset Type 1 diabetes: a randomised double-blind trial. Lancet 378(9788), 319-327 (2011).
9. Herold KC, Gitelman SE, Ehlers MR et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset Type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 62(11), 3766-3774 (2013).
10. Daifotis AG, Koenig S, Chatenoud L, Herold KC. Anti-CD3 clinical trials in Type 1 diabetes mellitus. Clin. Immunol. 149(3), 268-278 (2013).
11. Staeva TP, Chatenoud L, Insel R, Atkinson MA. Recent lessons learned from prevention and recent-onset Type 1 diabetes immunotherapy trials. Diabetes 62(1), 9-17 (2013).
12. Ludvigsson J, Cheramy M, Axelsson S et al. GAD-treatment of children and adolescents with recent-onset Type 1 diabetes preserves residual insulin secretion after 30 months. Diabetes Metab. Res. Rev. 30(5), 405-414 (2014).
13. Skyler JS, Krischer JP, Wolfsdorf J et al. Effects of oral insulin in relatives of patients with Type 1 diabetes: the Diabetes Prevention Trial - Type 1. Diabetes Care 28(5), 1068-1076 (2005).
14. Sosenko JM, Skyler JS, Beam CA et al. Acceleration of the loss of the first-phase insulin response during the progression to Type 1 diabetes in Diabetes Prevention Trial-Type 1 participants. Diabetes 62(12), 4179-4183 (2013).
15. Arif S, Leete P, Nguyen V et al. Blood and islet phenotypes indicate immunological heterogeneity in Type 1 diabetes. Diabetes 63(11), 3835-3845 (2014).
16. Huurman VA, Hilbrands R, Pinkse GG et al. Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. PLoS ONE 3(6), e2435 (2008).
17. Roep BO, Tree TI. Immune modulation in humans: implications for Type 1 diabetes mellitus. Nat. Rev. Endocrinol. 10(4), 229-242 (2014).
18. Imagawa A, Hanafusa T, Itoh N et al. Immunological abnormalities in islets at diagnosis paralleled further deterioration of glycaemic control in patients with recent-onset Type I (insulin-dependent) diabetes mellitus. Diabetologia 42(5), 574-578 (1999).
19. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329(14), 977-986 (1993).
20. Aschner PJ, Ruiz AJ. Metabolic memory for vascular disease in diabetes. Diabetes Technol. Ther. 14(Suppl. 1), S68-S74 (2012).
21. Wilson DM, Xing D, Cheng J et al. Persistence of individual variations in glycated hemoglobin: analysis of data from the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Randomized Trial. Diabetes Care 34(6), 1315-1317 (2011).
22. Lazar L, Ofan R, Weintrob N et al. Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed Type 1 diabetes: a randomised, double-blind Phase II study. Diabetes Metab. Res. Rev. 23(4), 286-291 (2007).
23. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet 383(9911), 69-82 (2014).
24. Vermeulen I, Weets I, Asanghanwa M et al. Contribution of antibodies against IA-2beta and zinc transporter 8 to classification of diabetes diagnosed under 40 years of age. Diabetes Care 34(8), 1760-1765 (2011).
25. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 358(9277), 221-229 (2001).
26. Barrett JC, Clayton DG, Concannon P et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of Type 1 diabetes. Nature Genet. 41(6), 703-707 (2009).
27. Schloot NC, Meierhoff G, Lengyel C et al. Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus Type 1: two prospective, randomized, double-blind Phase II trials. Diabetes Metab. Res. Rev. 23(4), 276-285 (2007).
28. Roark CL, Anderson KM, Simon LJ, Schuyler RP, Aubrey MT, Freed BM. Multiple HLA epitopes contribute to Type 1 diabetes susceptibility. Diabetes 63(1), 323-331 (2014).
29. Koeleman BP, Lie BA, Undlien DE et al. Genotype effects and epistasis in Type 1 diabetes and HLA-DQ trans dimer associations with disease. Genes Immun. 5(5), 381-388 (2004).
30. Kobayashi T, Tamemoto K, Nakanishi K et al. Immunogenetic and clinical characterization of slowly progressive IDDM. Diabetes Care 16, 780-788 (1993).
31. Harrison LC, Honeyman MC, De Aizpurua HJ et al. Inverse relation between humoral and cellular immunity to glutamic acid decarboxylase in subjects at risk of insulin-dependent diabetes. J. Endocrinol. Invest. 17, 581-581 (1994).
32. Roep BO, Duinkerken G, Schreuder GM, Kolb H, De VR, Martin S. HLA-associated inverse correlation between T cell and antibody responsiveness to islet autoantigen in recent-onset insulin-dependent diabetes mellitus. Eur. J. Immunol. 26(6), 1285-1289 (1996).
33. Mayr A, Schlosser M, Grober N et al. GAD autoantibody affinity and epitope specificity identify distinct immunization profiles in children at risk for Type 1 diabetes. Diabetes 56(6), 1527-1533 (2007).
34. Martin S, Wolf-Eichbaum D, Duinkerken G et al. Development of Type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N. Engl. J. Med. 345(14), 1036-1040 (2001).
35. Achenbach P, Koczwara K, Knopff A, Naserke H, Ziegler AG, Bonifacio E. Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to Type 1 diabetes. J. Clin. Invest. 114(4), 589-597 (2004).
36. Krause S, Landherr U, Agardh CD et al. GAD autoantibody affinity in adult patients with latent autoimmune diabetes, the study participants of a GAD65 vaccination trial. Diabetes Care 37(6), 1675-1680 (2014).
37. In't VP, Lievens D, De GJ et al. Screening for insulitis in adult autoantibody-positive organ donors. Diabetes 56(9), 2400-2404 (2007).
38. Howson JM, Stevens H, Smyth DJ et al. Evidence that HLA class I and II associations with Type 1 diabetes, autoantibodies to GAD and autoantibodies to IA-2, are distinct. Diabetes 60(10), 2635-2644 (2011).
39. Bingley PJ, Bonifacio E, Ziegler AG, Schatz DA, Atkinson MA, Eisenbarth GS. Proposed guidelines on screening for risk of Type 1 diabetes. Diabetes Care 24(2), 398 (2001).
40. Ziegler AG, Rewers M, Simell O et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 309(23), 2473-2479 (2013).
41. Orban T, Bundy B, Becker DJ et al. Co-stimulation modulation with abatacept in patients with recent-onset Type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 378(9789), 412-419 (2011).
42. Orban T, Bundy B, Becker DJ et al. Costimulation modulation with abatacept in patients with recent-onset Type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care 37(4), 1069-1075 (2014).
43. Huurman VA, Decochez K, Mathieu C, Cohen IR, Roep BO. Therapy with the hsp60 peptide DiaPep277 in C-peptide positive Type 1 diabetes patients. Diabetes Metab. Res. Rev. 23(4), 269-275 (2007).
44. Huurman VA, Van Der Meide PE, Duinkerken G et al. Immunological efficacy of heat shock protein 60 peptide DiaPep277 therapy in clinical Type I diabetes. Clin. Exp. Immunol. 152(3), 488-497 (2008).
45. Raz I, Avron A, Tamir M et al. Treatment of new-onset Type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, Phase II trial. Diabetes Metab. Res. Rev. 23(4), 292-298 (2007).
46. Ludvigsson J, Faresjo M, Hjorth M et al. GAD treatment and insulin secretion in recent-onset Type 1 diabetes. N. Engl. J. Med. 359(18), 1909-1920 (2008).
47. Ludvigsson J, Hjorth M, Cheramy M et al. Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset Type 1 diabetes: a randomised controlled trial. Diabetologia 54(3), 634-640 (2011).
48. Hagopian W, Ferry RJ Jr, Sherry N et al. Teplizumab preserves C-peptide in recent-onset Type 1 diabetes: two-year results from the randomized, placebo-controlled Protege trial. Diabetes 62(11), 3901-3908 (2013).
49. Sherry N, Hagopian W, Ludvigsson J et al. Teplizumab for treatment of Type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet 378(9790), 487-497 (2011).
50. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N. Engl. J. Med. 361(22), 2143-2152 (2009).
51. Nanto-Salonen K, Kupila A, Simell S et al. Nasal insulin to prevent Type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 372(9651), 1746-1755 (2008).
52. Knip M, Virtanen SM, Seppa K et al. Dietary intervention in infancy and later signs of beta-cell autoimmunity. N. Engl. J. Med. 363(20), 1900-1908 (2010).
53. Roep BO. Immune intervention therapy in Type 1 diabetes: safety first. Lancet Diabetes Endocrinol. 1(4), 263-265 (2013).
54. Hartemann A, Bensimon G, Payan CA et al. Low-dose interleukin 2 in patients with Type 1 diabetes: a Phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 1(4), 295-305 (2013).
55. Long SA, Rieck M, Sanda S et al. Rapamycin/IL-2 combination therapy in patients with Type 1 diabetes augments Tregs yet transiently impairs beta-cell function. Diabetes 61(9), 2340-2348 (2012).
56. Garside P, Mowat AM. Oral tolerance. Semin. Immunol. 13(3), 177-185 (2001).
57. Matthews JB, Staeva TP, Bernstein PL, Peakman M, Von Herrath M. Group I-JTDCTA: developing combination immunotherapies for Type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group. Clin. Exp. Immunol. 160(2), 176-184 (2010).